PDE5A and pulmonary arterial hypertension: The PDE5 inhibitor tadalafil was shown to improve LV diastolic function in patients with systemic sclerosis-associated PAH when combined with endothelin receptor antagonist ambrisentan [142], as well as in patients with resistant arterial hypertension [143].